Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Alkeon Capital Management LLC and Panayotis D. Sparaggis reported beneficial ownership of 1,591,104 shares of Hinge Health, Inc. Class A common stock, representing 5.7% of the class based on 26,799,441 shares outstanding as disclosed in the company prospectus dated May 23, 2025. The reported holdings include 1,215,093 Class A shares issuable upon conversion of Class B common stock.
The filing states the Reporting Persons have shared voting and dispositive power over 1,591,104 shares and no sole voting or dispositive power. The report lists Alkeon’s business office in New York and Hinge Health’s executive office in San Francisco and is signed by authorized representatives with an attached Joint Filing Agreement.
Hinge Health reported strong top-line growth alongside a large non-cash expense related to equity awards after completing its IPO. Revenue for the three months ended June 30, 2025 was $139.1 million, up from $89.8 million a year earlier, producing a gross profit of $97.8 million. Billings and deferred revenue increased, with deferred revenue at $275.1 million at June 30, 2025, reflecting billed but unrecognized subscription obligations.
Despite revenue growth, operating expenses surged to $678.4 million for the quarter, driven primarily by stock-based compensation. The company recorded a quarterly net loss of $575.7 million and an accumulated deficit of $1.08 billion. Cash and marketable securities remain substantial with cash and cash equivalents of $237.2 million and marketable securities of $176.1 million. In May 2025 the company completed an IPO, reclassified and converted preferred shares into common stock, repurchased Series E shares from a holder for $50.0 million, and used IPO proceeds to pay employee tax liabilities on equity settlements.